Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study
The Journal of Clinical Endocrinology & Metabolism2007Vol. 92(8), pp. 2977–2983
Citations Over TimeTop 10% of 2007 papers
Louis J. Aronne, Ken Fujioka, Vanita R. Aroda, Kim Chen, Amy E. Halseth, Nicole C. Kesty, Colleen Burns, Cameron W. Lush, Christian Weyer
Abstract
These results support continued evaluation of pramlintide as a potential treatment for obesity.
Related Papers
- → Amylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity(2017)128 cited
- → Amylin, Food Intake, and Obesity(2002)114 cited
- → Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats(2001)94 cited
- → Amylin(2017)40 cited
- Effect of N-terminus of Human Islet Amyloid Polypeptide on Amyloidogenicity and Cytotoxicity(2020)